AMNEAL PHARMACEUTICALS, INC. (AMRX) Return on equity 2018–2023
AMNEAL PHARMACEUTICALS, INC. (AMRX) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-424.6%FY2023 · since FY2018: -3.9% → -424.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2023 | -424.6% | -333.9 pp |
| FY2022 | -90.7% | -94.3 pp |
| FY2021 | 3.7% | -18.7 pp |
| FY2020 | 22.4% | +282.5 pp |
| FY2019 | -260.1% | -256.2 pp |
| FY2018 | -3.9% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More AMRX financial trends
AMRX RevenueAMRX Net incomeAMRX Net marginAMRX Gross profitAMRX Gross marginAMRX Operating incomeAMRX Operating marginAMRX Operating cash flowAMRX Free cash flowAMRX Capital expendituresAMRX Stock buybacksAMRX Dividends paidAMRX Total assetsAMRX Total liabilitiesAMRX Shareholders’ equityAMRX overview →